For this, Bertin Pharma uses these different cell models in order to screen your drug products and to highlight in cellulo their efficacy and their absence of cytotoxicity.

One reference molecule is tested in parallel of your drug products and 50, 70 & 90% effective and cytotoxic doses as well as selectivity index are systematically calculated.

Then, effects of lead compounds in primary cultures of relevant cells, their mode of action, their interactions with drugs routinely used in clinic are evaluated.

Cell & Animal Models

These initial results then lead naturally to pharmacokinetics (PK), early ADME and a proof of concept in animal models (mouse, rat, rabbit &Not Humanized primate – NHP) mimicking at best pathologies in Humans.

Indeed, many of our cell &/or animal models are designed to be as close as possible to the pathophysiology of target diseases).

All these following phases can be supported by Bertin Pharma and this is the same for regulatory Tox studies.

A Large Scope of Expertise relative to Candidates & Therapeutical Areas

Please find below the exhaustive list of candidates tested along with the relative therapeutical areas:

• NCE (New Chemical Entities)
• peptides or proteins including vaccine candidates, allergens, cytokines, etc.
• polysaccharides or lipids, lypopolysaccharides
• probiotics and inactivated vectors
• emulsions including dermatologic emulsions
• nanomaterials including nanoparticles
• infectious diseases
• cancer/oncology*
• neurodegenerative diseases e.g. MS
• autoimmune diseases e.g. SLE, Lupus
• metabolic & cardiovascular diseases e.g. diabetes, atherosclerosis
• asthma & allergy
• chronic inflammation
• dermatology, cosmetology
• nutrition

* In part, through a close partnership with Oncodesign